Skip to main content

Table 6 Bivariate Analysis Association between Comorbidities and SIBO

From: The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience

Variables SIBO, n (%) Total p value PR CI 95%
Yes No
DM, n (%)
 Yes 46 (38.3) 74 (61.7) 120 (100) 0.068 2.141 0.935–4.902
 No 9 (22.5) 31 (77.5) 40 (100)    
Dyslipidemia, n (%)
 Yes 43 (33.3) 86 (66.7) 129 (100) 0.571 0.792 0.352–1.780
 No 12 (38.7) 19 (61.3) 31 (100)    
Obesity, n (%)
 Yes 34 (31.8) 73 (68.2) 107 (100) 0.325 0.710 0.358–1.407
 No 21 (39.6) 21 (60.4) 53 (100)    
Metabolic Syndrome, n (%)
 Yes 42 (34.4) 80 (65.6) 122 (100) 0.980 1.010 0.469–2.174
 No 13 (34.2) 25 (65.8) 38 (100)    
Central Obesity, n (%)
 Yes 46 (30.9) 103 (69.1) 149 (100) 0.001 0.099 0.021–0.478
 No 9 (81.8) 2 (18.2) 11 (100)    
  1. SIBO Small Intestinal Bacterial Overgrowth, DM Diabetes Mellitus, PR Prevalence Ratio, CI Confidence Interval